Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.
Massachusetts, United States
|2021-05-26||NiKang Therapeutics||Series C||$200M||Ally Bridge Group, BlackRock, Casdin Capital, CBC Group, EcoR1 Capital, HBM Healthcare Investments, Invus Group, Janus Henderson Investors, Lilly Asia Ventures, Logos Capital, Matrix Partners China, Octagon Capital, Pavilion Capital, Perceptive Advisors, PFM Health Sciences, RA Capital Management, RTW Investments, Samsara BioCapital, Surveyor Capital, and Wellington Management|
|2021-05-20||Numab Therapeutics||Series C||$111M||BlackRock, BVF Partners, Forbion Capital Partners, HBM Partners, Novo Ventures, Octagon Capital, and RTW Investments|
|2021-05-18||Interius BioTherapeutics||Series A||$76M||Agent Capital, American Cancer Society, Bain Capital Ventures, BrightEdge, Fairmount Funds Management, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Mark Foundation for Cancer Research, Osage University Partners, Penn Medicine, Pfizer Venture Investments, Quan Capital, RA Capital Management, Tellus BioVentures, and University of Pennsylvania|
|2021-05-13||Elpiscience Biopharmaceuticals||Series C||$105M||CITIC securities Investment, Greater Bay Area Homeland Investments, Maison Capital, Qian Dao Fund, and Superstring Capital|